NAD+ in clinical practice
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for over 500 enzymatic reactions. Its roles span energy metabolism (as an electron carrier in the mitochondrial respiratory chain), DNA repair (as a substrate for PARP enzymes), epigenetic regulation (as a substrate for sirtuins), and cellular signalling. For clinicians, NAD+ is emerging as one of the most informative markers of cellular metabolic capacity and biological ageing.
Clinical significance of declining NAD+
NAD+ levels decline significantly with age — by some estimates, falling by 50% between age 40 and 60. This decline is associated with mitochondrial dysfunction, impaired DNA repair capacity, chronic inflammation (through dysregulated immune cell metabolism), and the progression of age-related diseases including neurodegeneration, cardiovascular disease, and metabolic syndrome. In clinical terms, low NAD+ may contribute to the fatigue, cognitive decline, and reduced resilience that many patients attribute simply to getting older.
Importantly, NAD+ depletion can be accelerated by factors beyond ageing alone: chronic alcohol consumption, high-calorie diets, circadian disruption, and conditions that increase DNA damage (UV exposure, chemotherapy) all consume NAD+ reserves faster than they can be replenished.
Monitoring NMN and NR supplementation
The rapid growth of the NAD+ precursor supplement market — primarily nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — has created a clinical need for objective monitoring. Patients are increasingly self-prescribing these supplements at varying doses, and without testing, there is no way to confirm whether supplementation is actually raising intracellular NAD+ levels. Testing provides the objective feedback loop that personalised supplementation strategies require.
When clinicians should consider NAD+ testing
NAD+ measurement is particularly relevant for patients presenting with unexplained fatigue and reduced exercise tolerance, individuals supplementing with NMN, NR, or IV NAD+ therapy (to verify efficacy), patients with neurodegenerative conditions or at genetic risk for Alzheimer's disease, those with chronic metabolic conditions (type 2 diabetes, metabolic syndrome), and clinicians operating in longevity or preventive medicine who want objective biomarker tracking alongside standard panels.
Frequently asked questions
Can NAD+ levels be improved?
Yes. NAD+ precursor supplements (NMN and NR) have been shown to raise blood NAD+ levels in human trials. Lifestyle interventions including exercise, caloric restriction, and circadian rhythm optimisation also support NAD+ maintenance. Testing confirms whether a given strategy is working for the individual patient.
Is NAD+ testing clinically validated?
While NAD+ testing is newer than established markers like cholesterol or HbA1c, the analytical methods (LC-MS/MS) are gold-standard and the association between NAD+ decline and age-related disease is well-supported in the peer-reviewed literature. It is increasingly used in research and clinical longevity settings.
Explore This Test
View method details, sample requirements, and reporting for our NAD+ Index.
View NAD+ Index →